Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Praxis Gains FDA Breakthrough Therapy Status for Elsunersen for Encephalopathy

Summary by Seeking Alpha
Praxis’ elsunersen wins FDA Breakthrough Therapy designation for SCN2A-related seizures. Read more here.

2 Articles

Seeking AlphaSeeking Alpha
Lean Right

Praxis gains FDA Breakthrough Therapy Status for elsunersen for encephalopathy

Praxis’ elsunersen wins FDA Breakthrough Therapy designation for SCN2A-related seizures. Read more here.

·United States
Read Full Article
Enid News & EagleEnid News & Eagle
Lean Left

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the ...

The Breakthrough Therapy Designation (BTD) was granted based on the positive results from theEMBRAVE Part A trial of elsunersen

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources lean Left, 50% of the sources lean Right
50% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Enid News & Eagle broke the news on Monday, June 22, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

FDA icon

FDA

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal